Alvotech and Abdi Ibrahim partner on biosimilars in Turkey

Icelandic biosimilars company Alvotech and leading Turkish drugmaker Abdi Ibrahim have entered into an exclusive partnership for the manufacturing and commercialization of Alvotech’s biosimilar portfolio for the Turkish market, the companies announced today.

Under the partnership, Alvotech will be responsible for the development and joint supply of multiple high value biosimilar assets from its current product pipeline, while Abdi Ibrahim will be responsible for joint manufacturing from its own facility, along with the registration and commercialization of these assets in Turkey.

Alvotech’s initial pipeline contains several biosimilar monoclonal antibodies and fusion proteins aimed at treating severe immune, inflammatory conditions, that improve the quality of life for patients around the world. Alvotech’s fully vertically integrated platform can support new products each year and over time create a substantial portfolio of high quality, high value products.